News

AstraZeneca and Ionis miss in key ATTR-CM trial

Jul 30, 2026

Indication and electrical performance of conventional, resynchronization, and conduction system pacing in transthyretin amyloid cardiomyopathy

BackgroundConduction system disorders and arrhythmias may require pacemaker (PM) or implantable cardioverter-defibrillator implantation in transthyretin amyloid…

Jul 29, 2026

Effect of Acoramidis on Heart Failure-Related Health Status: A Secondary Analysis of the ATTRibute-CM Randomized Clinical Trial

Jul 29, 2026

Acoramidis Attenuates Decline in Heart Failure–Related Health Status in ATTR-CM

Jul 28, 2026

Tafamidis Generic Wins EU Backing for ATTR Cardiomyopathy

Jul 28, 2026

Sex Differences in Presentation and Outcomes of Transthyretin Amyloid Cardiomyopathy

AbstractBackgroundTransthyretin amyloid cardiomyopathy (ATTR-CM) is more often diagnosed in men than in women but sex-specific data remain limited.ObjectivesThe…

Jul 27, 2026

AstraZeneca's Wainua Fails in ATTR-Cardiomyopathy, Ceding Ground to Stabilizers and Raising Class-Wide Risk for Gene Silencers

Jul 27, 2026

Alnylam Rises as Investors Weigh Pipeline Momentum, Earnings Setup, and ATTR-CM Positioning

Jul 27, 2026

Comprehensive AL Amyloidosis Market Summary, Epidemiology, Emerging Therapies, Competitive Landscape, Growth Trends, and Future Outlook Analysis

Jul 27, 2026

Less Advanced ATTR-CM Linked With 2-Year Survival on Tafamidis

Jul 27, 2026

Cell stress may play key role in triggering hATTR-PN

1
2
3
4
5
6
7
8
9
…
Next page
Last page

Subscribe to

RNAi Explained

Dr. Bersell explores RNA interference (RNAi) technology and its applications in treating ATTR-CM and ATTR-PN. Learn about mechanism of action, clinical evidence, and patient outcomes.

Learn More

Expert Perspectives on Attruby®

Dr. Barry Trachtenberg and ATTR community members discuss Attruby™ (acoramidis), covering clinical data, patient perspectives, and treatment considerations.

Watch Discussion